How do you approach the outpatient management of bispecific antibody therapy for hematologic malignancies?

Are you offering fully outpatient bispecific antibody treatment for lymphoma?

• Yes, treating outpatient for select low risk patients
• Yes, treating outpatient for most patients
• No, treating all patients with at least first cycles inpatient due to toxicity concerns
• No, treating all patients with at least first cycles inpatient due to logistical concerns (limited capacity for outpatient f/u, pharmacy needs, reimbursement etc)
• Other